SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0000947871-23-001055
Filing Date
2023-11-13
Accepted
2023-11-13 08:51:48
Documents
3
Group Members
ORBIMED CAPITAL GP VI LLCORBIMED GENESIS GP LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 7 ss2696773_sc13da.htm SC 13D/A 102566
2 JOINT FILING AGREEMENT ss2696773_ex9901.htm EX-99.1 6905
3 FORM OF LOCK-UP AGREEMENT ss2696773_ex9903.htm EX-99.3 30021
  Complete submission text file 0000947871-23-001055.txt   141253
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

IRS No.: 133976876 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address 188 EAST BLAINE ST., SUITE 200 SEATTLE WA 98102
Business Address 188 EAST BLAINE ST., SUITE 200 SEATTLE WA 98102 206-788-4545
ALPINE IMMUNE SCIENCES, INC. (Subject) CIK: 0001626199 (see all company filings)

IRS No.: 208969493 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-88896 | Film No.: 231395524
SIC: 2834 Pharmaceutical Preparations